Derms on Drugs

Get ready for a no-nonsense tour-de-force of practical application in the latest derm literature. Pipeline drugs, new approvals, brand names, generics—and HS data you’re better off ignoring (we’ll tell you why).

In this episode:

·       Leqselvi: the newest JAK for alopecia areata—actually different, or more of the same?

·       HS & spondyloarthritis: are you screening… should you be?

·       JAKs and the heart: are all cardiovascular risks created equal?

·       “2/3 HS remission” headlines: why this data shouldn’t change your practice

·       Tirbanibulin + cryo for AKs: combo win or marketing math?

·       Hydrochlorothiazide...

Listening this week could save your life (well, at least your kidneys).  Find out what common ingredient in keratin treatments you (and your friends, family and patients) NEED to avoid.  But there's a lot more than that packed into this week's episode.  As always, the Derms on Drugs bring the goods on the latest questions that the literature is answering:
-Is isotretinoin making kids short?  
-Is Dupixent making them tall?  
-What is "transcutaneous auricular vagus nerve stimulation" and which common but difficult derm disease does it help with?  
-What OTC supplement makes NBUVB work better for vit...

Admit it—bad hair days are the worst. Now imagine every day is one. Alopecia’s psychological impact is way deeper (and more surprising) than most people think. This week, the Derms on Drugs sit down with Harvard’s Dr. Maryanne Makredes Senna to unpack the mental side of AA—and then dive into what to do when a JAK inhibitor just… doesn’t JAK. As always, we’re answering the questions you didn’t even know you had.

Here’s what we’re tackling:

What hits harder on anxiety and depression—scarring or non-scarring alopecia?

How tigh...

This week, the Derms on Drugs are back with another literature speed-run—think 3D chess meets derm nerd nirvana. We’re answering questions you didn’t even know you had (and a few you wish you didn’t).

Here’s what we’re tackling:

Do herbal supplements turn up dermatomyositis?

Can biologics cut down on blood clots in HS?

Wait… does Claritin supercharge isotretinoin?

Is Sotyktu stirring up rosacea?

How good is the new oral IL-23 inhibitor icotrokinra for psoriasis?

Any fresh weapons against demodex?

Anything new fo...

The Derms on Drugs are joined by Dr. Crystal Aguh from Johns Hopkins for an AMAZING discussion on central centrifugal scarring alopecia.  From uber practical, cheap, safe, effective treatment approaches to deep science on what is happening in this disease, listen this week and you'll be an expert - how to talk to these patients, the baseline treatments everybody should be on, when to get more aggressive, when to step therapy back - the whole enchilada.  We even throw in a little frontal fibrosing alopecia.  Quite honestly one of the best episodes we've ever done.  The Derms on Drugs lear...

Join us this week as the Derms on Drugs crew discusses the latest in the Dermatology literature.  Topics for this episode include:

- Cutaneous vasculitis of the skin (it’s a Chapel Hill thing)

- Ozempic face, butt, and body

- TAC injections for AA – what concentration do you use?

- Does the MERLIN study deserve its magical name?

- Are systemic JAK inhibitors the answer for vitiligo?

- And everyone’s favorite – Demodex mites!

You don't see a lot of kids with psoriasis, but when you do it can be a big challenge, especially if it's bad and they need a systemic.  The Derms on Drugs are coming to the rescue!  We'll have a special guest - Dr. Doug Kress (who was heavily involved in training all three of the Derms on Drugs) who has enormous experience treating pediatric psoriasis.  We'll get into all the stuff you really need to know:
-What systemic drugs are approved for psoriasis under the age of 18?
-What does the data say about which ones work the...

Brought to you by Scholars In Medicine

 The Derms on Drugs take on the latest, greatest and coolest stuff from the Derm literature.  Quite honestly, there was some stuff this week that just seems crazy and that you won't want to miss.  Join us as we discuss questions like: 
 
-Do tattoos protect people against melanoma? 
-What cheap, easy topical works great for fissures in hand eczema? 
-Is Dupixent safe in pregnancy? 
-Are tinted sunscreens actually better than regular mineral sunscreens for melasma? 
-If an alopecia areata patient has failed two or three JAKs...

Join the Derms on Drugs and Dr. Shanthi Narla as we dive into the world of obesity, GLP-1s and dermatology.  Whatever you think about all of these topics, we promise that your patients are hearing about them, reading about them and will be asking about them.  Specifically, we'll get into the latest data about how GLP-1s affect diseases like psoriasis, hidradenitis suppurativa and atopic dermatitis and we'll even touch on if dermatologists should be prescribing GLP-1s.  So, while there aren't any definite answers out there yet, tune in this week and you'll be ready when these hot...

Join the Derms on Drugs as we slice and dice the latest dermatology literature.  We've got stuff that will change what you do next week, answers for uncommon but challenging diseases and the latest updates on the pharma pipeline.  We'll answer burning questions, like:
-When is the best time to start niacinamide for skin cancer prevention?
-Which drugs work the best for the itch of atopic dermatitis and prurigo nodularis?
-Is minoxidil 5 mg actually better than minoxidil 2.5 mg?
-What can do when for PLEVA that's not responding to the usual treatments?
-Is icotrokinra (the ne...

Join the Derms on Drugs as we slice and dice the latest dermatology literature.  We've got stuff that will change what you do next week, answers for uncommon but challenging diseases and the latest updates on the pharma pipeline.  We'll answer burning questions, like:
-When is the best time to start niacinamide for skin cancer prevention?
-Which drugs work the best for the itch of atopic dermatitis and prurigo nodularis?
-Is minoxidil 5 mg actually better than minoxidil 2.5 mg?
-What can do when for PLEVA that's not responding to the usual treatments?
-Is icotrokinra (the ne...

Ever wonder if you can trust those network meta-analyses (NMAs) flooding dermatology journals? Join the Derms on Drugs and University of Toronto expert Dr. Aaron Drucker for a critical deep dive into NMAs—what they are, how they work, and whether dermatologists should rely on them for treatment decisions.

NMAs promise head-to-head comparisons for drugs without having to do a head-to-head trial, especially in psoriasis, hidradenitis suppurativa, atopic dermatitis, and soon alopecia areata. But here's the catch: different NMAs on the same topic can give conflicting results about which treatments work best.

In th...

Welcome back to Derms on Drugs! Today we’re cracking open a six-pack—not IPAs, but papers.

We’ve got polyomavirus antibodies sneaking in as early markers for Merkel cell recurrence, collagen supplements promising to smooth wrinkles or just make your bank accounts smaller, and ruxolitinib cream stepping up for the disaster that is chronic hand eczema.

But wait—there’s more! Isotretinoin is back, this time for seb derm instead of acne, actinic cheilitis gets the meta-analysis glow-up, lentigo maligna sees radiation face off against imiquimod, and atopic dermatitis therapies can shake up the skin microb...

Join the Derms on Drugs and Dr. Marc Serota (who is triple boarded in dermatology, allergy and pediatrics) to find out the latest on how to think about the causes of chronic spontaneous urticaria - it can be autoimmune, it can literally be an "allergy to yourself" or it can be neither of the above.  Crucially, there are clinical clues to which one it is, and if you can figure out which one it is, it helps predict the response to therapy!
So join us for a deep dive into CSU, and yes, there will be trivia at t...

Get ahead of the curve with Derms on Drugs as we break down the most exciting new dermatology research! This week features game-changing studies including an oral probiotic with stunning results for atopic dermatitis, JAK inhibitors for bullous pemphigoid, and IL-23 inhibitors tackling guttate psoriasis.

Plus, we dive deep into:

Dermoscopy advances for managing longitudinal melanonychia

If failing an IL-13 inhibitor affects the chances of doing well on another IL-13 inhibitor

New data on IL-13 inhibitor induced conjunctivitis

Red light PDT efficacy for superficial basal cell carcinoma

...

Stay at the forefront of dermatology with the Derms on Drugs and their special guest Dr. Scott Drew! This episode is a rapid-fire roundup of the latest journal pearls-perfect for busy practitioners looking to keep up with the latest evidence in the literature.

We cover:

Older systemic drugs aren’t just relics—they’re critical tools for dermatologists tackling all kinds of medical diseases - whether we're talking about patients who can't access (or don't respond adequately) to our highly effective FDA approved drugs for psoriasis, atopic dermatitis, alopecia areata, hidradenitis or about patients with diseases that don't have an extremely effective FDA approved drug - things like lichen planus, granuloma annulare, dermatitis herpetiformis and many, many more.  This week, we talk through dapsone, roflumilast, and acitretin.
In this episode, you’ll learn:

Perfect for dermatology providers who want up-to-date, actionable advice on...

The Derms on Drugs take on the latest, greatest and coolest stuff from the Derm literature.  Quite honestly, there was some stuff this week that just seems crazy and that you won't want to miss.  Join us as we discuss questions like:
-Do tattoos protect people against melanoma?
-What cheap, easy topical works great for fissures in hand eczema?
-Is Dupixent safe in pregnancy?
-Are tinted sunscreens actually better than regular mineral sunscreens for melasma?
-If an alopecia areata patient has failed two or three JAKs, is it worth trying another one?
-What do...

Older systemic drugs aren’t just relics—they’re critical tools for dermatologists tackling tough diseases like lichen planus, granuloma annulare, psoriasis, atopic dermatitis, and alopecia areata, especially when FDA-approved options fall short or are inaccessible. Join Derms on Drugs and guest expert Dr. Scott Drew as we share practical pearls for using methotrexate, mycophenolate, cyclosporine, dapsone, roflumilast, and more.
In this episode, you’ll learn:
--When and why to reach for these time-tested therapies in real-world practice
--How to monitor labs and counsel patients for safety and success
--Tips for discussing off-label treatments and navigati...

Today on Derms on Drugs we’ve got the fabulous Dr. Heather Woolery-Lloyd with us, and yes—we’re talking sunscreens. Don’t roll your eyes, because we’re going way past “SPF 30 or 50?” into the good stuff: how these lotions and potions actually work, which myths need to finally get buried, and why tinted sunscreens aren’t just makeup but legit medicine for skin of color.

We’ll also dish on the brand-new Aussie rules for UV protection and spill which brands actually look good on darker skin without turning you into a ghost.

And because no epi...

Welcome back to another episode of Derms on Drugs—where we prescribe only the highest yield practical pearls (and zero prior authorizations are ever required). If dermatology conferences make you yawn but a six-pack of journal articles gets your heart racing, you’re definitely in the right clinic!

What’s on Tap in Our 6 Pack Episode?

Today, we’re serving up a refreshing six-pack—no ice needed, but plenty of cool research to keep you hydrated with knowledge:

Welcome to another episode of Derms on Drugs, where we peel back the layers on the latest in dermatology therapeutics. Today, we’re thrilled to have Dr. Donna Culton join us for a deep dive into the world of bullous pemphigoidIn this episode we:

Welcome to the first-ever Derms on Drugs Debate! Our brave hosts tackle three of the hottest—and most controversial—questions in the field:

Castle Gene Expression Profile in Melanoma: Should dermatologists use it for almost every melanoma, just those “close to 1 mm,” or leave it to the oncologists?

Zoryve, VTAMA and Opzelura: All great drugs, but if you could only keep one, which would it be? Our hosts go head-to-head to defend their picks.

The Next Game Changer in Dermatology: Will it be AI-powered skin cancer diagnosis, BTK inhibitors, or the first generic oral JAK? H...

Ready to level up your medical dermatology game? This week, Derms on Drugs tackles the toughest questions and latest controversies in serious derm—served with our signature practical, no-nonsense style with a big dose of humor.
We break down the newest literature and answer:
Does immunotherapy really help with high-risk squamous cell carcinoma?
Are pemphigus patients getting more rituximab than they need?
Why don’t JAK inhibitors increase cardiovascular risk in atopic dermatitis?
Is the Mind.Px test actually helpful for picking a psoriasis biologic?
What does drug level monitoring tell us about adal...

Chronic Spontaneous Urticaria (CSU) is back in the dermatology spotlight—and for good reason. Join the Derms on Drugs as we break down the latest clinical trial data on Dupixent (dupilumab) and the buzzworthy new oral BTK inhibitor, remibrutinib, both showing real promise for CSU patients who’ve hit a wall with antihistamines.
We’re joined by CSU expert Dr. Jason Hawkes to discuss:

-How Dupixent is changing the game for CSU and why dermatologists are leading the charge

-What makes remibrutinib “fast, sexy, and safe”—plus what the new Phase III data means f...

Ready to stay ahead in dermatology? Join the Derms on Drugs for a fast-paced, practical dive into the hottest new research and trends shaping our specialty.

This week, we break down:

Surprising long-term data comparing Dupixent and Rinvoq for atopic dermatitis

The future of autoimmune disease treatment: genetically modified T cells

What policies people actually support (and will pay for) to reduce skin cancer rates

JAK inhibitors for mucosal pemphigoid—what’s new, what works, and what to watch for

The latest on rising contact allergens: which ones...

Ever feel overwhelmed by the flood of alopecia treatments and supplements?

Join the Derms on Drugs as we cut through the noise with Dr. Michelle Tarbox, diving deep into the practical side of managing alopecia for dermatology providers.

In this episode, we tackle:

Tune in for expert insights, practical tips, and a healthy dose of humor—perfect fo...

Hair loss is common and devastating, both to the person losing their hair and the dermatology provider taking care of them.  Derms on Drugs to the rescue.  In part one of our deep dive into hair loss we cover three big topics:  1) What supplements for hair loss actually work?  You'll have heard (ad nauseum) about some of them, but we'll also bring you some ideas for cheap supplements you haven't heard of that actually work; 2) Do we really need to do lab work-ups in patients with telogen effluvium? and 3) What's the state of the art when it comes to diag...

Join Derms on Drugs for a must-hear episode packed with practical dermatology updates!

Discover if Nutrafol Acne delivers, which skin care ingredients top cosmetic dermatologists swear by, and the latest breakthroughs for hand eczema. Plus, is Zoryve Foam a game-changer for psoriasis? And what’s the deal with PRAME staining for benign nevi? Get actionable insights to elevate your practice along with our usual banter. 

Derms on Drugs is produced by Scholars in Medicine.

Resource links can be found at: Scholarsinmedicine.com
1.  A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial for the Efficacy and Safe...

 Skyrocketing drug prices are hitting dermatology hard. Why are Americans paying more than other countries? Are Pharmacy Benefit Managers (PBMs) or pharmaceutical companies to blame? Join Derms on Drugs as our experts pull back the curtain on the broken system driving costs. Get insider insights, practical takeaways, and our trademark banter to navigate this mess as a clinician.

Derms on Drugs is a production of Scholarsinmedicine.com

1.  Use and Cost of First-Line Biologic Medications to Treat Plaque Psoriasis in the US
2.  Systematic review and estimated cost-efficacy of biologics compared with narrowband ultr...

Join Derms on Drugs for a riveting dive into artificial intelligence and automated skin cancer detection.

World-renowned expert Dr. Laura Ferris, with 20 years in the field, breaks down cutting-edge research and predicts the future of dermatology. Will AI "terminate" dermatologists or empower us to focus on complex cases and patient care? Expect fresh insights, practical takeaways, and lively banter that’ll make you a smarter clinician. Don’t miss this chance to stay ahead in the AI revolution!

Derms on Drugs is produced by ⁠Scholars In Medicine

For Resources links visit: ⁠Scholars In Medic...

Tune in to Derms on Drugs for a the most fun you can have while diving into the hottest dermatology topics! This week, we unpack cutting-edge insights from the latest literature to make you a sharper clinician. Explore adjuvant therapy for Stage 3A melanoma, the pitfalls of dermatomyositis misdiagnosis, and a surprising finding: is hydroxychloroquine outperforming NBUVB for vitiligo?

Plus, discover new skin-gut-immune connections, tackle cancer immunotherapy-induced pemphigoid, and learn how to manage premenstrual rash flares in atopic dermatitis, contact dermatitis, and autoimmune progesterone dermatitis. Join our fun, banter-filled discussion to stay ahead in dermatology!

Should dermatologists offer Image Guided Superficial Radiation Therapy (IGSRT) in-office or refer radiation oncologists when radiation is appropriate? Join Derms on Drugs as we tackle this "burning" question with two expert radiation oncologists. While dermatologists are THE skin cancer experts, radiation therapy isn't our usual domain— so is IGSRT a game-changer for your practice or too far outside our realm? Explore clinical insights, practical considerations, and the latest evidence to guide your decision-making. Perfect for dermatologists, PAs, NPs, residents, medical students, and pharma professionals in dermatology seeking to stay ahead of the curve. Tune in to discover if IGSRT co...

Buckle up for a whirlwind tour of the hottest dermatology literature. This week, we’ve got the deets on:

Hidradenitis suppurat...

When a pathology report says 'melanoma,' the stakes are high. How confident are you in the diagnosis? Should you order gene expression profiling for better prognostic insights—or is it overrated?

Join the Derms on Drugs as we dig into the challenges of melanoma diagnosis and management. This week, we’re thrilled to feature Dr. Whitney High from the University of Colorado, the best-of-the-best dermatopathology expert, to share evidence-based answers with the Derms on Drugs flare our listeners expect.  

Derms on Drugs is brought to you by ⁠⁠Scholars in Medicine.⁠

Resource...

Does Dupixent raise the risk of cutaneous T-cell lymphoma (CTCL) in atopic dermatitis patients? It’s the burning question gripping dermatology—and we’ve got answers.

Join the Derms on Drugs team as we unpack the latest with Dr. Shamir Geller, who runs a CTCL clinic at Memorial Sloan Kettering and published the first data that truly helps us understand if there is a Dupixent - CTCL link.

Plus, we dive into CTCL survival stats and must-know updates for practicing dermatologists. Essential listening for anyone who is taking care of dermatology patients.

Derms on Dru...

Late-breaking abstracts from the AAD Meeting offer a sneak peek into dermatology’s future—and we’ve done the heavy lifting for you. Derms on Drugs uncovers the hottest data that will dominate the top journals and meetings in 2025: the cutting-edge for psoriasis, new Tyk2 inhibitors, new treatment for cutaneous lupus, dupilumab’s possible role in bullous pemphigoid, patient-led patch testing innovations, plus fresh approaches to skin cancer and alopecia areata. Tune in to stay ahead of the curve!

This podcast is brought to you by Scholars in Medicine.

New Articles on causes and treatments for AKs, Melasma, Atopic Derm, Acne, Grover's and Contact Derm.  But you can't always believe what you read in a journal, and even when you can it doesn't mean it's going to help your patients.  So, sit back, relax and join the Derms on Drugs to separate fact from fiction.

The Derms on Drugs enlist the Sultan of Scratching, Dan Kaplan from the University of Pittsburgh, to answer the age- old question - should you scratch an itch or not? 

Believe it or not, some of the most cutting-edge science on the planet is focusing on this question (you think they'd have better stuff to work on, but who are we to judge). The answer(s) are going to surprise you - turns out scratching does a lot more than just get bugs off our skin (although that part is important too).

Derms on Drugs is...

The Captain of Compliance, The Admiral of Adherence... Whatever you want to call him, you're going to love this week's episode as the Derms on Drugs dig deep with Dr. Steve Feldman on how to help our patients actually follow through with our recommendations. Trust us, even if you've heard Dr. Feldman talk about this before, you're still not going to want to miss this.

As part of our dive into the nitty gritty of adherence we'll also talk about:
-The first "Oral Biologic" on the way from Janssen - is this oral peptide that inhibits I...

-Big BCCs – Debulk First or Chemo First?; 

-Do Covid or the Covid Vaccine Affect the Risk of Getting a Bullous Disease?

-Does Drinking Drive Melasma?

But of course that’s not all: Should we be treating Strep to help our psoriasis patients get better faster? What Biologics are new on the horizon for treating linear morphea? And just how well does oral roflumilast work for psoriasis?

Join us this week for more dermatology takes that you won’t get anywhere else!

Derms on Drugs is brought to you by ⁠Scholars in...

Psoriasiform Dermatitis - the Derms on Drugs take on your worst nightmare when it comes to path reports.  Dermatitis?  Psoriasis?  Both?  Neither?  We'll get into the weeds with Amber Atwater, who looked at what the final diagnoses ended up being in hundreds of patients with psoriasiform dermatitis that gives us some clues on how to approach these patients. We also review the latest work on idiopathic erythroderma - not so idiopathic anymore, thanks to the hard work and genius of Shawn Kwatra at the University of Maryland. And, stick around to the end for some hard hitting trivia on the A...

We all kind of freaked out when the news broke that benzene had been detected in benzoyl peroxide. I mean, makes sense, right -benzene even sounds like benzoyl - how did nobody think of this before! And the lab that detected it got Zantac pulled from the market and it was even discussed at Fall Clinical..."There is no safe amount of exposure to benzene..." The final straw was when an article dropped in JID -JID for goodness sake - about the problem.

Not so fast. Our trio did a deep dive and there is WAY more to this story than meets the eye. Join u...

Litfulo for when all hope for hair seems lost...when Olumiant strikes out, can Litfulo pinch hit and save the day? Hand eczema: Did we really need a 60,000-patient study to find out who's most likely to have horrible hands? The Hand Eczema Whisperer: Jacob Thyssen joins us all the way from the University of Copenhagen for some hand-to-hand combat: What causes it, what can you do about it right now, and what's on the horizon for hand eczema. But that's not all — the Derms on Drugs always bring the best stuff from the literature.

Derms on...

Is your Litfulo not pulling its weight? New research gives you the inside scoop on when to throw in the towel

We’re buzzing about oral JAK inhibitors for vitiligo, but do they really outshine NBUVB alone? We’ve got the answer 

And guess what? While basking in the sun might up your skin cancer risk, it turns out those rays also help you dodge death from heart disease, cancer and other nasty surprises— at least if you happen to be living in England

Join Richard Weller, the genius behind these sacrilege statements, as he h...

Buckle-up Kids.  Our Derms on Drugs are answering some of the hottest questions in dermatology again this week:

Buckle up! We're diving deep into the wild world of dermatology, where the only thing more dangerous than a weird mole is a boxed warning. Here's what's cooking in this episode: